News
PDSB
1.390
-2.11%
-0.030
Weekly Report: what happened at PDSB last week (0106-0110)?
Weekly Report · 1d ago
Weekly Report: what happened at PDSB last week (1230-0103)?
Weekly Report · 01/06 10:13
Weekly Report: what happened at PDSB last week (1223-1227)?
Weekly Report · 12/30/2024 10:09
Weekly Report: what happened at PDSB last week (1216-1220)?
Weekly Report · 12/23/2024 10:13
PDS Biotechnology (PDSB) Receives a Buy from Alliance Global Partners
TipRanks · 12/19/2024 10:17
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 12/18/2024 11:51
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 12/18/2024 11:41
Promising Advancements in Cancer Treatment Drive Buy Rating for PDS Biotechnology
TipRanks · 12/18/2024 11:26
Weekly Report: what happened at PDSB last week (1209-1213)?
Weekly Report · 12/16/2024 10:14
Weekly Report: what happened at PDSB last week (1202-1206)?
Weekly Report · 12/09/2024 10:12
PDS BIOTECHNOLOGY REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/06/2024 13:00
PDS Biotechnology Corporation Announces Key Opinion Leader Event on HPV16-Positive Head and Neck Cancer and Phase 3 Clinical Trial for Versamune® HPV
Barchart · 12/03/2024 17:20
Weekly Report: what happened at PDSB last week (1125-1129)?
Weekly Report · 12/02/2024 10:12
PDS Biotechnology Price Target Cut to $7.00/Share From $9.00 by B. Riley Securities
Dow Jones · 11/25/2024 16:55
PDS Biotechnology Is Maintained at Buy by B. Riley Securities
Dow Jones · 11/25/2024 16:55
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
Benzinga · 11/25/2024 16:45
PDS Biotechnology price target lowered to $7 from $9 at B. Riley
TipRanks · 11/25/2024 13:35
Strategic Changes in PDS Biotechnology’s Clinical Trial Design Position Stock as Attractive Buy Opportunity
TipRanks · 11/25/2024 12:45
PDS BIOTECHNOLOGY CORP <PDSB.O>: B. RILEY CUTS TARGET PRICE TO $7 FROM $9
Reuters · 11/25/2024 11:53
Weekly Report: what happened at PDSB last week (1118-1122)?
Weekly Report · 11/25/2024 10:08
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.